AXSM Stock Risk & Deep Value Analysis
Axsome Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About AXSM Stock
We analyzed Axsome Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran AXSM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is AXSM Stock?
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Low
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for AXSM?
- ⚠
FDA Complete Response Letter (CRL) or rejection for AXS-05 in AD Agitation
- ⚠
Slower-than-expected commercial adoption of Auvelity/Sunosi
- ⚠
Competitive product launches in key markets
- ⚠
Negative results from ongoing clinical trials
Unlock AXSM Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Axsome Therapeutics Inc (AXSM) Do?
Market Cap
$9.21B
Sector
Healthcare
Industry
Biotechnology
Employees
816
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Visit Axsome Therapeutics Inc WebsiteIs AXSM Stock Undervalued?
Unlock the full AI analysis for AXSM
Get the complete DVR score, risk analysis, and more
Does AXSM Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily driven by strong patent protection for Auvelity and other pipeline candidates, offering exclusivity for several years. Successful commercialization and established physician adoption will further reinforce this through brand recognition and inherent switching costs in chronic disease management.
Moat Erosion Risks
- •Patent challenges or loss of exclusivity
- •Emergence of superior or cheaper treatment alternatives
- •Regulatory changes impacting drug development or commercialization
AXSM Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive AXSM Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated Early May 2026)
- •Continued commercial sales growth for Auvelity & Sunosi
- •Potential updates on AXS-05 (Auvelity) for AD Agitation regulatory pathway
Medium-Term (6-18 months)
- •Potential FDA PDUFA date for AXS-05 in AD Agitation (if not yet announced/passed)
- •Launch and initial commercial ramp of Auvelity for AD Agitation
- •Phase 3 trial results for AXS-12 (narcolepsy) or AXS-07 (migraine)
Long-Term (18+ months)
- •Peak sales achievement for Auvelity across indications (MDD, AD Agitation)
- •Expansion of pipeline into new CNS disorders
- •Establishment as a leading CNS pharmaceutical company
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for AXSM?
- ✓
FDA decision/PDUFA date for AXS-05 in AD Agitation
- ✓
Auvelity commercial sales acceleration
- ✓
Progress and data readout for AXS-12 (narcolepsy)
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for AXSM (Axsome Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
